Genedrive (GDR)

Sector:

Health Care

Index:

FTSE AIM All-Share

 1.83p
   
  • Change Today:
      0.000p
  • 52 Week High: 22.25p
  • 52 Week Low: 1.80p
  • Currency: UK Pounds
  • Shares Issued: 154.32m
  • Volume: 90,760
  • Market Cap: £2.82m
  • RiskGrade: 747

Genedrive test to go through new, faster NICE process

By Josh White

Date: Monday 26 Sep 2022

LONDON (ShareCast) - (Sharecast News) - Molecular diagnostics technology company Genedrive announced on Monday that the UK's National Institute for Health and Clinical Excellence (NICE) has transferred the evaluation of its 'MT-RNR1' test to a new 'early value assessment programme'.
The AIM-traded firm said the programme is a new review process, created to drive innovation into the hands of healthcare professionals by actively drawing in digital products, medical devices and diagnostics that address national unmet needs.

It said the programme would allow the NICE diagnostics advisory committee to consider the technology "much faster", resulting in a published report in a six month timeframe instead of the initial 63 weeks - approximately 14 months - via the diagnostics assessment programme.

A provisional schedule was published by NICE, indicating the consultation process would occur in February.

Genedrive described the MT-RNR1 assay as "the world's first" rapid point-of-care test to screen infants in an urgent care setting for a genetic variant that would cause life-long hearing loss when carriers of the variant were given certain antibiotics.

Those that carry the variant could then be given alternative treatments following detection of the variant by the Genedrive test.

"We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive MT-RNR1 test has been fast tracked via their new EVA programme, which may allow clinicians and patients to benefit from the test sooner," said chief executive officer David Budd.

"This is a testament to our technology and our ability to address this unmet need."

At 1309 BST, shares in Genedrive were up 2.13% at 12p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Genedrive Market Data

Currency UK Pounds
Share Price 1.83p
Change Today 0.000p
% Change 0.00 %
52 Week High 22.25p
52 Week Low 1.80p
Volume 90,760
Shares Issued 154.32m
Market Cap £2.82m
RiskGrade 747

Genedrive Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
12.43% below the market average12.43% below the market average12.43% below the market average12.43% below the market average12.43% below the market average
6.25% above the sector average6.25% above the sector average6.25% above the sector average6.25% above the sector average6.25% above the sector average
Price Trend
97.8% below the market average97.8% below the market average97.8% below the market average97.8% below the market average97.8% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Income Not Available
Growth
43.14% below the market average43.14% below the market average43.14% below the market average43.14% below the market average43.14% below the market average
66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average66.67% below the sector average

Genedrive Dividends

No dividends found

Trades for 20-May-2024

Time Volume / Share Price
09:13 2,000 @ 1.84p
08:57 37,748 @ 1.84p
08:36 54 @ 1.85p
08:36 216 @ 1.85p
08:36 54 @ 1.85p

Genedrive Key Personnel

CFO Russell Shaw
CEO James Cheek

Top of Page